Cushing's Disease

Research on Cushing's disease, a condition caused by excess cortisol production typically due to a pituitary adenoma secreting ACTH. Studies evaluate urinary free cortisol normalization, ACTH suppression, and clinical symptom improvement.

Quick Answer

What it is

Research on Cushing's disease, a condition caused by excess cortisol production typically due to a pituitary adenoma secreting ACTH. Studies evaluate urinary free cortisol normalization, ACTH suppression, and clinical symptom improvement.

Key findings

  • Grade A: Urinary Free Cortisol Normalization (Pasireotide (Signifor))
  • Grade A: ACTH Secretion (Pasireotide (Signifor))
  • Grade A: Cushing's Disease Symptoms (Pasireotide (Signifor))

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

ℹ️ Quick Facts

Quick Facts: Cushing's Disease

  • Supplements Studied:1
1 supps · 3 outcomes

Detailed Outcomes

A
Urinary Free Cortisol Normalization
Phase III: 25% achieved UFC normalization at 6 months. 76% showed UFC decrease. Rapid reduction within 1-2 months, sustained up to 24 months.
large↓Improves
A
ACTH Secretion
Direct inhibition of ACTH release from corticotroph adenomas. Phase II showed decreased ACTH in majority of patients within 15 days.
large↓Improves
A
Cushing's Disease Symptoms
Improvements in clinical signs including weight, blood pressure, and metabolic parameters maintained over 24 months of treatment.
moderate↓Improves

Research Citations (47)

Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis.
(2025)
PMID: 39527181
Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia.
(2025)
PMID: 40165498
Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.
(2025)
PMID: 39842795
Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis.
(2025)
PMID: 40622518
Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis.
(2024)
PMID: 39349787
Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.
(2023)
PMID: 37233978
Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation.
(2023)
PMID: 37388858
Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.
(2022)
PMID: 35518928
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis.
(2022)
PMID: 35846311
Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
(2021)
PMID: 33248230

Related Conditions